September 2020 - Page 31 of 31

TuesdaySep 01, 2020 9:20 am

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) Starts Presentation at The LD 500

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical-stage drug development company with a platform technology designed to address multibillion-dollar markets in the treatment of cancer, inflammatory disease and COVID-19. The company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC) and successfully achieved its primary endpoint in a Phase II trial for treating nonalcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line…

TuesdaySep 01, 2020 9:20 am

Aptorum Group Limited (NASDAQ: APM) Starts Presentation at The LD 500

Aptorum Group Limited (NASDAQ: APM) is a biopharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease. The company's current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women's health supplement, dioscorea opposita bioactive nutraceutical tablets, marketed under the brand name NativusWell. To date, Aptorum has obtained 11 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology,…

TuesdaySep 01, 2020 9:20 am

Annovis Bio Inc. (NYSE American: ANVS) Starts Presentation at The LD 500

Annovis Bio Inc. (NYSE American: ANVS) is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. With an aging population, neurodegenerative diseases have become one of the world's largest unmet medical needs. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain. Annovis is developing novel treatments that are expected to improve memory loss and dementia associated with Alzheimer's disease and Alzheimer's in Down Syndrome, as well as body and brain function in Parkinson's disease. Annovis has an ongoing…

TuesdaySep 01, 2020 9:00 am

IMAC Holdings Inc. (NASDAQ: IMAC) Starts Presentation at The LD 500

IMAC Holdings Inc. (NASDAQ: IMAC) was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement-restricting diseases and conditions. IMAC owns or manages 16 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, multiple Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMAC's outpatient medical…

TuesdaySep 01, 2020 9:00 am

VolitionRX Ltd. (NYSE American: VNRX) Starts Presentation at The LD 500

VolitionRX Ltd. (NYSE American: VNRX) is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the lives of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. For more…

TuesdaySep 01, 2020 9:00 am

Sono-Tek Corp. (OTCQX: SOTK) Starts Presentation at The LD 500

Sono-Tek Corp. (OTCQX: SOTK) is the leading developer and manufacturer of ultrasonic coating systems for applying precise, thin film coatings to protect, strengthen or smooth surfaces on parts and components for the microelectronics/electronics, alternative energy, medical and industrial markets. This includes specialized glass applications in construction and automotive. The company's solutions are environmentally friendly, efficient and highly reliable. They enable dramatic reductions in overspray and savings in raw material, water and energy usage, while also providing improved process repeatability, transfer efficiency, uniformity and emissions. For more information, visit the company's website at www.sono-tek.com About The LD 500 The LD 500…

TuesdaySep 01, 2020 9:00 am

Issuer Direct Corp. (NYSE American: ISDR) Starts Presentation at The LD 500

Issuer Direct Corp. (NYSE American: ISDR) is an industry-leading communications and compliance company. It primarily focuses on the needs of corporate issuers. Issuer Direct's principal platform, Platform id. (TM), empowers users by thoughtfully integrating the most relevant tools, technologies and services, thus eliminating the complexity associated with producing and distributing financial and business communications. It provides disclosure management solutions, shareholder communications tools and cloud-based compliance technologies. The company serves a diverse range of client bases in the financial services industry, including brokerage firms, banks, mutual funds, accounting agencies and the legal communities. Headquartered in Raleigh, North Carolina, Issuer Direct serves…